15^th Biosimilar Market Report

Q4 2026

We are pleased to present the 15th edition of our Biosimilar Market Report, offering our latest analysis of US pricing and market share dynamics across key biosimilar markets.

The US biosimilar market continues to evolve amid growing emphasis on supply reliability and access stability. Following our previous coverage of policy changes shaping the biosimilar landscape, this edition turns to another critical dimension: the current state of biosimilar supply shortages and the broader implications for supply chain resilience. Recent disruptions have highlighted the importance of manufacturing capacity, distribution networks, and inventory management.

In this quarter's deep-dive section, we examine the biosimilar supply shortage landscape and its impact on market dynamics. We analyze key factors contributing to supply constraints, explore how supply chain stability influences product adoption and contracting decisions, and discuss both the challenges and strategic opportunities that biosimilar stakeholders should consider in building more resilient supply frameworks.

Thank you for your ongoing engagement with our reports. Our report continues to offer an in-depth perspective on current market trends, challenges, and strategic opportunities for stakeholders navigating this rapidly changing landscape.

© 2026 Samsung Bioepis Co., Ltd. All Rights Reserved. 10/2026.